Equipoise (Boldenone Undecylenate)

01 Overview

Equipoise 200mg/ml 5 vial 2 ml c/u 5 vials

02 Details

 

Equipoise

 (Boldenone Undecylenate)

Ba-29038; Boldenone Undecylenate (USAN); Boldénone, Undécylénate de; Boldenoni Undecylenas; 1-Dehydrotestosterone (boldenone); Undecilenato de boldenona. 17β-Hydroxyandrosta-1,4-dien-3-one 17-(undec-10-enoate). Болденона Ундециленат

C30H44O3 = 452.7.

CAS — 846-48-0 (boldenone); 13103-34-9 (boldenone undecenoate).

Equipoise contains: 200mg

  • 200 mg / ml Boldenone undecylenate

 

Pharmacologic Category

Androgen

Dosing

 

  1. a) 1 mg/kg IM; may repeat in 1 week intervals (most will respond with one or two treatments)
  2. b) 3 mg/kg IM; repeated at 1 week intervals (Robinson 1987)

Indications and Clinical Uses

Boldenone is an anabolic agent. It is used primarily to improve nitrogen balance, reduce overexertion associated with exercise, and improve training. It may also improve appetite and improve weight gain when used with a well-balanced diet.

Boldenone is a long-lasting agent, and effects may persist for 6 weeks after an intramuscular injection.

 

Storage/Stability

 

Boldenone injection should be stored at room temperature; avoid freezing. Because it is in an oil vehicle, it should not be physically mixed with any other medications. Store in a tightly sealed container, protected from light, do not mix with aqueous solutions.

 

Contraindications/Precautions/Warnings

In humans, anabolic agents are contraindicated in patients with hepatic dysfunction, hypercalcemia, patients with a history of myocardial infarction (can cause hypercholesterolemia), pituitary insufficiency, prostate carcinoma, in selected patients with breast carcinoma, benign prostatic hyper trophy and during the nephrotic stage of nephritis.

Adverse Effects

Detrimental effect in testis size, and sperm production and quality in males. In females, the drug caused fewer total and large follicles, smaller ovaries, increased clitoral size, reduced pregnancy rates and severely altered sexual behavior.

Anabolic steroids have the potential to cause hepatic toxicity.

Pregnancy Risk Factor

 

Category X: Studies in animals or human beings have demonstrated fetal abnormalities, or there is evidence of fetal risk based on human experience, or both, and the risk of the use of the drug in pregnant women clearly outweighs any possible benefit. The drug is contraindicated in women who are or may become pregnant.

 

Pregnancy Considerations

Use is contraindicated in women who are or may become pregnant; masculinization of the fetus has been reported.

Lactation

Excretion in breast milk unknown/not recommended

Overdosage/Acute Toxicity

In humans, sodium and water retention can occur after overdosage of anabolic steroids. It is suggested to treat supportively and monitor liver function should an inadvertent overdose be administered; there is no information available in animals.

Mechanism of Action

In the presence of adequate protein and calories, anabolic steroids promote body tissue building processes and can reverse catabolism.

As these agents are either derived from or are closely related to testosterone, the anabolics have varying degrees of androgenic effects.

Endogenous testosterone release may be suppressed by inhibiting luteinizing hormone (LH). Large doses can impede spermatogenesis by negative feedback inhibition of FSH.

Anabolic steroids can also stimulate erythropoiesis possibly by stimulation of erythropoietic stimulating factor. Anabolics can cause nitrogen, sodium, potassium and phosphorus retention and decrease the urinary excretion of calcium.

Pharmacokinetics

No specific information was located for this agent. It is considered a long-acting anabolic, with effects persisting up to 8 weeks. It is unknown if the anabolic agents cross into milk.

 

Drug Interactions

The following drug interactions have either been reported or are theoretical in humans or animals receiving anabolic steroids

Anticoagulants (warfarin): Anabolic agents as a class may potentiate the effects of anticoagulants; monitoring of INR and dosage adjustment of the anticoagulant (if necessary) are recommended

Corticosteroids: Anabolics may enhance the edema that can be associated with ACTH or adrenal steroid therapy.

Insulin: Diabetic patients receiving insulin may need dosage adjustments if anabolic therapy is added or discontinued; anabolics may decrease blood glucose and decrease insulin requirements.

Test Interactions

Concentrations of protein bound iodine (PbI) can be decreased in patients receiving androgen/anabolic therapy, but the clinical significance of this is probably not important

Androgen/anabolic agents can decrease amounts of thyroxine­binding globuline and decrease total T4 concentrations and increase resin uptake of T3and T4; free thyroid hormones are unaltered and, clinically, there is no evidence of dysfunction.

Both creatinine and creatine excretion can be decreased by anabolic steroids.

Anabolic steroids can increase the urinary excretion of 17­ketos­teroids.

Androgenic/anabolic steroids may alter blood glucose levels.

Androgenic/anabolic steroids may suppress clotting factors II,  V, VII, and X.

Anabolic agents can affect liver function tests (BSP retention, SGOT, SGPT, bilirubin, and alkaline phosphatase)

 

Monitoring

  • Androgenic side effects
  • Fluid and electrolyte status, if indicated
  • Liver function tests if indicated
  • Red blood cell count, indices, if indicated
  • Weight, appetite

 

Dosage Forms

Boldenone Undecylenate for Injection: 25 mg/mL in 10 mL vials; 200 mg/mL in 10 mL and 50 mL vials; 200mg/ml in 1 ml.